Cystic Fibrosis - Institute for Respiratory Health

Cystic Fibrosis

Study Outline

The study aims to evaluate the safety and efficacy of VX-121/tezacaftor/deutivacaftor in cystic fibrosis patients.

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

Eligibility & Requirements

  • Aged 18 or over with a diagnosis of cystic fibrosis

What's Involved

  • The total study duration is approximately 64 weeks.
  • It involves 13 visits to the Institute for Respiratory Health at the QEII Medical Centre in Nedlands and 6 phone call follow-ups.
Principal Investigator
Dr Siobhain Mulrennan
Register your interest in this Clinical Trial
  • This field is for validation purposes and should be left unchanged.
Current Clinical Trials